Compare BIO-TECHNE Corp (TECH) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Uranium Energy Corp — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Uranium Energy Corp trades at $11.5 (market cap $5.63B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| TECH | UEC | |
|---|---|---|
Market Cap | $11.24B | $5.63B |
Sector | Health | Energy |
52-Week High | $72.29 | $20.14 |
52-Week Low | $43.31 | $9.04 |
Enterprise Value | $11.32B | $5.14B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
UEC trades at $11.26, up 4.65% in the last 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces profitability challenges with a negative net income margin of -513.24%. Recent news highlights optimism around nuclear energy growth, but financial performance remains under pressure.
Outlook is mixed: strong analyst buy ratings (87.5%) and sector tailwinds support potential, but persistent losses, high P/S ratio of 265.97, and execution risks pose significant challenges. Investors should weigh the speculative growth narrative against fundamental weaknesses and cash flow concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
